Key facts
- Pathomation’s last known valuation is $1.9M (Jan 2025).
- It has raised $900K; the latest was Later Stage VC ($830K) in Jan 2025.
- Notable investors include EIT Health, Imec.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Pathomation
- ·The full record, as it builds
Funding rounds
No funding rounds for Pathomation are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pathomation
Operator of digital pathology software intended for diagnostics, research, and education purposes. The company's platform supports whole slide image viewing and management with cloud and on-premise deployment, compatibility with nearly all scanner formats, integration with existing lab and education systems, support for consensus scoring in AI validation, tools for virtual microscopy training, web-based collaboration, and a modular architecture, enabling clients to manage, analyze, and share pathology images efficiently across varied environments.
- Sector
- Healthcare
- HQ
- Antwerp, Belgium
- Founded
- 2012
- Employees
- 12
- Website
- pathomation.com/
- Ownership
- Privately Held (backing)
Pathomation doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pathomation shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pathomation in its N-PORT filings yet. We sweep new filings monthly.